SOSV

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing gene therapy treatments specifically for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, the company utilizes proprietary technology to deliver therapeutic DNA directly to intestinal stem cells, aiming to address the underlying causes of diseases such as Familial Adenomatous Polyposis (FAP), a hereditary form of colorectal cancer that often necessitates invasive surgical procedures. By targeting these root causes, DNALite seeks to prevent disease progression rather than merely managing symptoms, offering a potentially transformative approach to treating gastrointestinal disorders, including colorectal cancer and Crohn's disease.

Genetsis Group operates as a digital marketing agency, specializing in marketing strategy, development, and management in digital environments. The company provides a range of services, including data marketing, CRM strategy and activation, business intelligence, e-commerce optimization, and marketing automation. Additionally, Genetsis Group offers digital agency services such as campaign strategy, design and user experience, social media management, mobile development, and analytics. The firm is focused on delivering integrated digital communication and multiplatform interactive design, while also assisting businesses in executing digital transformation strategies to enhance customer experiences and improve operational efficiency. Founded in 1994, Genetsis Group is headquartered in Alcobendas, Spain, with additional offices in Shanghai, San Francisco, and Mexico City.

Moirai Biodesign develops RNA-based therapies and diagnostics for cancer. The company develops non-invasive tests for in-vitro and in-situ diagnosis of AML using the patients blood; in-vivo diagnosis systems for surgical assistance and patient monitoring; and therapeutical drugs for treating cancer. Its pipeline includes RNA biomarker discovery, plug and play bio device design, and platform delivery system. The company was founded in 2016 and is based in Ireland.

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing gene therapy treatments specifically for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, the company utilizes proprietary technology to deliver therapeutic DNA directly to intestinal stem cells, aiming to address the underlying causes of diseases such as Familial Adenomatous Polyposis (FAP), a hereditary form of colorectal cancer that often necessitates invasive surgical procedures. By targeting these root causes, DNALite seeks to prevent disease progression rather than merely managing symptoms, offering a potentially transformative approach to treating gastrointestinal disorders, including colorectal cancer and Crohn's disease.

ArgenTAG specializes in developing synthetic DNA barcoding technology aimed at enhancing the capabilities of long-read sequencing applications in genomics. By addressing the limitations associated with reduced multiplexing capacity and sequencing throughput, ArgenTAG enables the simultaneous analysis of thousands of samples. The company integrates advanced micro-fabrication techniques with next-generation DNA sequencing and molecular biology, leveraging reengineered error correction technologies initially derived from digital communications. This innovative approach facilitates the decentralization of genome sequencing, allowing medical professionals to effectively analyze antibodies and perform single-cell sequencing, thus advancing the field of personalized medicine.

ArgenTAG specializes in developing synthetic DNA barcoding technology aimed at enhancing the capabilities of long-read sequencing applications in genomics. By addressing the limitations associated with reduced multiplexing capacity and sequencing throughput, ArgenTAG enables the simultaneous analysis of thousands of samples. The company integrates advanced micro-fabrication techniques with next-generation DNA sequencing and molecular biology, leveraging reengineered error correction technologies initially derived from digital communications. This innovative approach facilitates the decentralization of genome sequencing, allowing medical professionals to effectively analyze antibodies and perform single-cell sequencing, thus advancing the field of personalized medicine.

Circularis Biotechnologies, Inc. is a biotechnology company established in 2014 and based in California. The company focuses on developing innovative methods to regulate gene expression, aiming to enhance the production yields of biotherapeutics. Circularis offers a range of products, including RACRE Variant Libraries, hCMV Variant Library, and T7 Variant Library, as well as services such as RACRE Enhancement, RACRE Discovery, RACRE Technology Access Program, and Ribozyme Analysis of Cis-Regulatory Elements. By improving the targeting of gene therapy and optimizing gene expression in under-researched organisms, Circularis seeks to advance the fields of gene therapy, biomanufacturing, and synthetic biology, ultimately benefiting medical practitioners and enhancing therapeutic outcomes.

Gatehouse Bio is a biotechnology company based in Waltham, Massachusetts, focused on advancing precision medicine through the development of targeted therapeutics. Founded in 2016, the company utilizes a novel bioinformatics platform to identify small ribonucleic acid (sRNA) biomarkers, which are essential for uncovering disease signatures and facilitating drug discovery and repurposing. Their technology employs machine learning to achieve high accuracy in classifying patient samples, making it a valuable tool for identifying custom biomarker panels tailored to individual needs. Gatehouse Bio collaborates with leading drug developers to discover novel drug targets and develop companion diagnostics, with applications validated in areas such as cardiology, neurology, oncology, respiratory diseases, and rare diseases.

Sequential Skin is a diagnostic platform company targeting skin longevity and aging. Our team specialises in genetics, epigenetics, and the skin microbiome.

DropGenie is a biotechnology company founded in 2018 and based in Montreal, Canada. The company focuses on developing connected hardware that automates gene editing processes, thereby enhancing the efficiency of genetic engineering. Its platform streamlines liquid handling and experimental conditions, which helps scientists reduce costs while improving the standardization and reproducibility of their work. By generating standardized and compatible scientific information, DropGenie aims to accelerate the pace of discovery in the field of genetics, making advancements in gene editing more accessible to researchers.

Catalog Technologies Inc. is a Boston-based company that specializes in a DNA-based platform designed for digital data storage and computation. Founded in 2016, Catalog's innovative platform encodes digital information into DNA, providing a new approach to long-term data archiving. This method not only enhances data storage capacity but also offers a cost-effective solution for managing vast amounts of information. By integrating advanced synthetic biology technologies, Catalog aims to revolutionize the way digital data is archived and processed, making DNA a viable medium for future data storage needs.

Indee Labs is developing hardware for gene delivery. Our hardware is uniquely positioned for the efficient development and scalable manufacture of gene-modified cell therapies such as chimeric antigen receptor T cells. The technology is being developed with the help of the Australian National Fabrication Facility. We are alumni of NSW Health, IndieBio, Y Combinator and MBC Biolabs (née QB3@953). We are opening up an office in Sydney and have lab space at Bonneville Labs in Berkeley.

Sequential Skin is a diagnostic platform company targeting skin longevity and aging. Our team specialises in genetics, epigenetics, and the skin microbiome.

Helex uses its own genomics data, bioinformatics, and intelligent data-driven platform to create, verify, and distribute therapy-specific gRNAs. Founded in 2021 and is based in New York.

Helex uses its own genomics data, bioinformatics, and intelligent data-driven platform to create, verify, and distribute therapy-specific gRNAs. Founded in 2021 and is based in New York.

Microgenesis SA is a biotechnology company focused on developing medical technologies and treatments for reproductive health. Established in 1992 and based in San José de la Rinconada, Spain, the company specializes in non-invasive tests that identify imbalances in vaginal and intestinal microbiota linked to infertility. Additionally, Microgenesis offers dual tests to assess microbiota imbalances related to endometrial immunological issues and provides tools and guidance for managing complex reproductive health cases. Their innovative fertility test and treatment aim to restore fertility potential, particularly for women who have previously experienced multiple IVF failures. Operating from a CLIA-certified lab in Oakland, Microgenesis emphasizes a drug-free, all-natural three-month treatment that addresses subclinical inflammation adversely affecting ovarian function and implantation.

Avalo is a biotechnology company focused on enhancing crop resilience through innovative gene discovery and control techniques. By employing interpretable machine learning, Avalo accelerates the identification of genes in plants, thereby facilitating the development of improved agricultural crops. The company's artificial intelligence-based platform is designed to uncover the biological origins of traits essential for future agriculture, such as drought tolerance, water-use efficiency, and nutrient density. This advancement in gene discovery not only aids researchers in validating and predicting crop quality but also addresses the challenges posed by a changing climate, contributing to a healthier and more sustainable agricultural landscape.

Sequential Skin is a diagnostic platform company targeting skin longevity and aging. Our team specialises in genetics, epigenetics, and the skin microbiome.

CyGenica specializes in developing innovative delivery solutions for drugs, gene editing components, and antibiotics using a non-viral, non-toxic platform. The company focuses on creating molecular devices that facilitate the programmable delivery of anticancer drugs and other therapeutic agents directly into cells. These devices are designed to cross cellular membrane barriers, allowing for the effective transport of functional molecules into the cytoplasm and various cellular organelles. By enabling pharmaceutical and biotechnology companies to develop new types of anticancer drugs with extended brand lifecycles, CyGenica aims to enhance the efficacy and safety of medical treatments.

Pregenerate, Inc. is a biotechnology company founded in 2019 and incorporated in Delaware. It specializes in developing scalable organ-on-a-chip models aimed at replacing animal testing in medical and pharmaceutical research, particularly for arthritis treatments. By utilizing human cells in its innovative models, Pregenerate's technology not only enhances the efficiency of drug development but also improves success rates for bringing new medications to market. Furthermore, this approach allows for the stratification of patients into specific treatment subgroups, enabling healthcare providers to tailor therapies to individual needs. This focus on personalized medicine aims to significantly reduce the costs associated with traditional testing methods while advancing the understanding of treatment responses in patients with arthritis.

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing gene therapy treatments specifically for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, the company utilizes proprietary technology to deliver therapeutic DNA directly to intestinal stem cells, aiming to address the underlying causes of diseases such as Familial Adenomatous Polyposis (FAP), a hereditary form of colorectal cancer that often necessitates invasive surgical procedures. By targeting these root causes, DNALite seeks to prevent disease progression rather than merely managing symptoms, offering a potentially transformative approach to treating gastrointestinal disorders, including colorectal cancer and Crohn's disease.

Avalo is a biotechnology company focused on enhancing crop resilience through innovative gene discovery and control techniques. By employing interpretable machine learning, Avalo accelerates the identification of genes in plants, thereby facilitating the development of improved agricultural crops. The company's artificial intelligence-based platform is designed to uncover the biological origins of traits essential for future agriculture, such as drought tolerance, water-use efficiency, and nutrient density. This advancement in gene discovery not only aids researchers in validating and predicting crop quality but also addresses the challenges posed by a changing climate, contributing to a healthier and more sustainable agricultural landscape.

Avalo is a biotechnology company focused on enhancing crop resilience through innovative gene discovery and control techniques. By employing interpretable machine learning, Avalo accelerates the identification of genes in plants, thereby facilitating the development of improved agricultural crops. The company's artificial intelligence-based platform is designed to uncover the biological origins of traits essential for future agriculture, such as drought tolerance, water-use efficiency, and nutrient density. This advancement in gene discovery not only aids researchers in validating and predicting crop quality but also addresses the challenges posed by a changing climate, contributing to a healthier and more sustainable agricultural landscape.

Gypsy Bay Genomics is combining scientific backgrounds in genomics and oncology with startup expertise to translate genetic discoveries into advances in personalized clinical care as it strives to develop technology that will decrease the rates of cervical cancer globally.

Gypsy Bay Genomics is combining scientific backgrounds in genomics and oncology with startup expertise to translate genetic discoveries into advances in personalized clinical care as it strives to develop technology that will decrease the rates of cervical cancer globally.

Sequential Skin is a diagnostic platform company targeting skin longevity and aging. Our team specialises in genetics, epigenetics, and the skin microbiome.

Microgenesis SA is a biotechnology company focused on developing medical technologies and treatments for reproductive health. Established in 1992 and based in San José de la Rinconada, Spain, the company specializes in non-invasive tests that identify imbalances in vaginal and intestinal microbiota linked to infertility. Additionally, Microgenesis offers dual tests to assess microbiota imbalances related to endometrial immunological issues and provides tools and guidance for managing complex reproductive health cases. Their innovative fertility test and treatment aim to restore fertility potential, particularly for women who have previously experienced multiple IVF failures. Operating from a CLIA-certified lab in Oakland, Microgenesis emphasizes a drug-free, all-natural three-month treatment that addresses subclinical inflammation adversely affecting ovarian function and implantation.

Gatehouse Bio is a biotechnology company based in Waltham, Massachusetts, focused on advancing precision medicine through the development of targeted therapeutics. Founded in 2016, the company utilizes a novel bioinformatics platform to identify small ribonucleic acid (sRNA) biomarkers, which are essential for uncovering disease signatures and facilitating drug discovery and repurposing. Their technology employs machine learning to achieve high accuracy in classifying patient samples, making it a valuable tool for identifying custom biomarker panels tailored to individual needs. Gatehouse Bio collaborates with leading drug developers to discover novel drug targets and develop companion diagnostics, with applications validated in areas such as cardiology, neurology, oncology, respiratory diseases, and rare diseases.

Sequential Skin is a diagnostic platform company targeting skin longevity and aging. Our team specialises in genetics, epigenetics, and the skin microbiome.

Sequential Skin is a diagnostic platform company targeting skin longevity and aging. Our team specialises in genetics, epigenetics, and the skin microbiome.

Gatehouse Bio is a biotechnology company based in Waltham, Massachusetts, focused on advancing precision medicine through the development of targeted therapeutics. Founded in 2016, the company utilizes a novel bioinformatics platform to identify small ribonucleic acid (sRNA) biomarkers, which are essential for uncovering disease signatures and facilitating drug discovery and repurposing. Their technology employs machine learning to achieve high accuracy in classifying patient samples, making it a valuable tool for identifying custom biomarker panels tailored to individual needs. Gatehouse Bio collaborates with leading drug developers to discover novel drug targets and develop companion diagnostics, with applications validated in areas such as cardiology, neurology, oncology, respiratory diseases, and rare diseases.

Magellan Life Sciences Ltd. is a synthetic biology company based in London, United Kingdom, established in 2018. The company specializes in developing proprietary protein engineering and expression platforms to create innovative plant-inspired proteins, such as brazzein, for applications in the food and beverage industries. Additionally, Magellan Life Sciences offers the XSeed platform, which leverages synthetic biology to advance the development of novel proteins aimed at enhancing the food, health, and nutrition sectors.

Moirai Biodesign develops RNA-based therapies and diagnostics for cancer. The company develops non-invasive tests for in-vitro and in-situ diagnosis of AML using the patients blood; in-vivo diagnosis systems for surgical assistance and patient monitoring; and therapeutical drugs for treating cancer. Its pipeline includes RNA biomarker discovery, plug and play bio device design, and platform delivery system. The company was founded in 2016 and is based in Ireland.

Pregenerate, Inc. is a biotechnology company founded in 2019 and incorporated in Delaware. It specializes in developing scalable organ-on-a-chip models aimed at replacing animal testing in medical and pharmaceutical research, particularly for arthritis treatments. By utilizing human cells in its innovative models, Pregenerate's technology not only enhances the efficiency of drug development but also improves success rates for bringing new medications to market. Furthermore, this approach allows for the stratification of patients into specific treatment subgroups, enabling healthcare providers to tailor therapies to individual needs. This focus on personalized medicine aims to significantly reduce the costs associated with traditional testing methods while advancing the understanding of treatment responses in patients with arthritis.

Microgenesis SA is a biotechnology company focused on developing medical technologies and treatments for reproductive health. Established in 1992 and based in San José de la Rinconada, Spain, the company specializes in non-invasive tests that identify imbalances in vaginal and intestinal microbiota linked to infertility. Additionally, Microgenesis offers dual tests to assess microbiota imbalances related to endometrial immunological issues and provides tools and guidance for managing complex reproductive health cases. Their innovative fertility test and treatment aim to restore fertility potential, particularly for women who have previously experienced multiple IVF failures. Operating from a CLIA-certified lab in Oakland, Microgenesis emphasizes a drug-free, all-natural three-month treatment that addresses subclinical inflammation adversely affecting ovarian function and implantation.

Microgenesis SA is a biotechnology company focused on developing medical technologies and treatments for reproductive health. Established in 1992 and based in San José de la Rinconada, Spain, the company specializes in non-invasive tests that identify imbalances in vaginal and intestinal microbiota linked to infertility. Additionally, Microgenesis offers dual tests to assess microbiota imbalances related to endometrial immunological issues and provides tools and guidance for managing complex reproductive health cases. Their innovative fertility test and treatment aim to restore fertility potential, particularly for women who have previously experienced multiple IVF failures. Operating from a CLIA-certified lab in Oakland, Microgenesis emphasizes a drug-free, all-natural three-month treatment that addresses subclinical inflammation adversely affecting ovarian function and implantation.

Sun Genomics, Inc. is a microbiome health company based in San Diego, California, specializing in customized probiotics aimed at addressing dysbiosis. Founded in 2014, the company’s flagship product, Floré, combines a gut microbiome test with personalized probiotic formulations tailored to individual gut profiles, assessed through whole-genome sequencing. The Floré Gut Test includes a microflora collection kit, a comprehensive microflora profile analysis, and wellness consultations. Additionally, Sun Genomics offers Floré Tots, a probiotic solution designed for children up to age 12, which comes in a convenient powder form that can be easily mixed with beverages. The company sells its products online, providing an automatic renewal service to enhance customer convenience.

Genetsis Group operates as a digital marketing agency, specializing in marketing strategy, development, and management in digital environments. The company provides a range of services, including data marketing, CRM strategy and activation, business intelligence, e-commerce optimization, and marketing automation. Additionally, Genetsis Group offers digital agency services such as campaign strategy, design and user experience, social media management, mobile development, and analytics. The firm is focused on delivering integrated digital communication and multiplatform interactive design, while also assisting businesses in executing digital transformation strategies to enhance customer experiences and improve operational efficiency. Founded in 1994, Genetsis Group is headquartered in Alcobendas, Spain, with additional offices in Shanghai, San Francisco, and Mexico City.

DropGenie is a biotechnology company founded in 2018 and based in Montreal, Canada. The company focuses on developing connected hardware that automates gene editing processes, thereby enhancing the efficiency of genetic engineering. Its platform streamlines liquid handling and experimental conditions, which helps scientists reduce costs while improving the standardization and reproducibility of their work. By generating standardized and compatible scientific information, DropGenie aims to accelerate the pace of discovery in the field of genetics, making advancements in gene editing more accessible to researchers.

Ivy Natal is a biotechnology company focused on developing a novel process to create human egg cells from skin samples. By utilizing a skin biopsy technology, the company activates the existing DNA in skin cells to transform them into healthy egg cells. This innovative approach addresses many challenges associated with traditional methods of producing eggs and sperm in vitro, providing a potential solution for various infertility cases. Ivy Natal's technology aims to offer couples, including same-sex couples, the opportunity to have genetically related children.

Ivy Natal is a biotechnology company focused on developing a novel process to create human egg cells from skin samples. By utilizing a skin biopsy technology, the company activates the existing DNA in skin cells to transform them into healthy egg cells. This innovative approach addresses many challenges associated with traditional methods of producing eggs and sperm in vitro, providing a potential solution for various infertility cases. Ivy Natal's technology aims to offer couples, including same-sex couples, the opportunity to have genetically related children.

Circularis Biotechnologies, Inc. is a biotechnology company established in 2014 and based in California. The company focuses on developing innovative methods to regulate gene expression, aiming to enhance the production yields of biotherapeutics. Circularis offers a range of products, including RACRE Variant Libraries, hCMV Variant Library, and T7 Variant Library, as well as services such as RACRE Enhancement, RACRE Discovery, RACRE Technology Access Program, and Ribozyme Analysis of Cis-Regulatory Elements. By improving the targeting of gene therapy and optimizing gene expression in under-researched organisms, Circularis seeks to advance the fields of gene therapy, biomanufacturing, and synthetic biology, ultimately benefiting medical practitioners and enhancing therapeutic outcomes.

Briefcase Biotec develops KiloBaser, a Nespresso machine of DNA synthesis - enabling cutting edge research without detours. KiloBaser is a device for printing short synthetic DNA sequences. It enables individual scientists to easily produce the DNA they need on their desktops, while speeding up production of the basics for all genetic engineering and synthetic biology research and development. Headquartered in Graz, Steiermark, KiloBaser was founded in 2013 by Martin Jost and Alexander Murer.

Catalog Technologies Inc. is a Boston-based company that specializes in a DNA-based platform designed for digital data storage and computation. Founded in 2016, Catalog's innovative platform encodes digital information into DNA, providing a new approach to long-term data archiving. This method not only enhances data storage capacity but also offers a cost-effective solution for managing vast amounts of information. By integrating advanced synthetic biology technologies, Catalog aims to revolutionize the way digital data is archived and processed, making DNA a viable medium for future data storage needs.

Moirai Biodesign develops RNA-based therapies and diagnostics for cancer. The company develops non-invasive tests for in-vitro and in-situ diagnosis of AML using the patients blood; in-vivo diagnosis systems for surgical assistance and patient monitoring; and therapeutical drugs for treating cancer. Its pipeline includes RNA biomarker discovery, plug and play bio device design, and platform delivery system. The company was founded in 2016 and is based in Ireland.

Farma Genetix is a Boston-based company that specializes in the manufacture of genetically tailored natural supplements and personalized diet plans aimed at addressing chronic health conditions. The company collaborates with researchers from Harvard Medical School's Genomics department to develop nutritional supplements designed to support cardiovascular health, including the maintenance of healthy blood pressure and cholesterol levels. Through its customized diet plans, Farma Genetix promotes a holistic approach to health that reinforces overall well-being and a healthy lifestyle.

Sun Genomics, Inc. is a microbiome health company based in San Diego, California, specializing in customized probiotics aimed at addressing dysbiosis. Founded in 2014, the company’s flagship product, Floré, combines a gut microbiome test with personalized probiotic formulations tailored to individual gut profiles, assessed through whole-genome sequencing. The Floré Gut Test includes a microflora collection kit, a comprehensive microflora profile analysis, and wellness consultations. Additionally, Sun Genomics offers Floré Tots, a probiotic solution designed for children up to age 12, which comes in a convenient powder form that can be easily mixed with beverages. The company sells its products online, providing an automatic renewal service to enhance customer convenience.

Ravata Solutions, founded in 2016 and based in Davis, California, specializes in developing medical devices for gene delivery, focusing on the creation of custom animal models. The company is dedicated to enhancing the production of transgenic models, which are crucial for pre-clinical research studies aimed at improving human disease modeling. By optimizing embryo viability and streamlining the process of creating transgenic organisms, Ravata enables researchers to conduct their studies more efficiently. This innovation has significant implications for advancing drug efficacy and medical genetics research, ultimately contributing to the development of better therapies and understanding of human diseases.

Dahlia Biosciences specializes in the fields of biotechnology and DNA analysis and diagnostics. The company provides a single-cell RNA analysis tools for research and diagnostic applications. Dahlia Biosciences was founded in 2011 and headquartered in California, United States.

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing gene therapy treatments specifically for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, the company utilizes proprietary technology to deliver therapeutic DNA directly to intestinal stem cells, aiming to address the underlying causes of diseases such as Familial Adenomatous Polyposis (FAP), a hereditary form of colorectal cancer that often necessitates invasive surgical procedures. By targeting these root causes, DNALite seeks to prevent disease progression rather than merely managing symptoms, offering a potentially transformative approach to treating gastrointestinal disorders, including colorectal cancer and Crohn's disease.

DropGenie is a biotechnology company founded in 2018 and based in Montreal, Canada. The company focuses on developing connected hardware that automates gene editing processes, thereby enhancing the efficiency of genetic engineering. Its platform streamlines liquid handling and experimental conditions, which helps scientists reduce costs while improving the standardization and reproducibility of their work. By generating standardized and compatible scientific information, DropGenie aims to accelerate the pace of discovery in the field of genetics, making advancements in gene editing more accessible to researchers.

Sun Genomics, Inc. is a microbiome health company based in San Diego, California, specializing in customized probiotics aimed at addressing dysbiosis. Founded in 2014, the company’s flagship product, Floré, combines a gut microbiome test with personalized probiotic formulations tailored to individual gut profiles, assessed through whole-genome sequencing. The Floré Gut Test includes a microflora collection kit, a comprehensive microflora profile analysis, and wellness consultations. Additionally, Sun Genomics offers Floré Tots, a probiotic solution designed for children up to age 12, which comes in a convenient powder form that can be easily mixed with beverages. The company sells its products online, providing an automatic renewal service to enhance customer convenience.

Chronomics Ltd, established in 2017 and headquartered in Norwich, United Kingdom, specializes in testing kits and an artificial intelligence platform designed for DNA methylation analysis. The company focuses on monitoring users' health and wellbeing by utilizing epigenetic information derived from DNA. Its offerings include insights into biological age, smoke exposure, metabolic state, health risks, and hereditary intolerances, along with predictions related to eye color. Through its innovative approach, Chronomics aims to provide a comprehensive understanding of individual health profiles.

Pregenerate, Inc. is a biotechnology company founded in 2019 and incorporated in Delaware. It specializes in developing scalable organ-on-a-chip models aimed at replacing animal testing in medical and pharmaceutical research, particularly for arthritis treatments. By utilizing human cells in its innovative models, Pregenerate's technology not only enhances the efficiency of drug development but also improves success rates for bringing new medications to market. Furthermore, this approach allows for the stratification of patients into specific treatment subgroups, enabling healthcare providers to tailor therapies to individual needs. This focus on personalized medicine aims to significantly reduce the costs associated with traditional testing methods while advancing the understanding of treatment responses in patients with arthritis.

Briefcase Biotec develops KiloBaser, a Nespresso machine of DNA synthesis - enabling cutting edge research without detours. KiloBaser is a device for printing short synthetic DNA sequences. It enables individual scientists to easily produce the DNA they need on their desktops, while speeding up production of the basics for all genetic engineering and synthetic biology research and development. Headquartered in Graz, Steiermark, KiloBaser was founded in 2013 by Martin Jost and Alexander Murer.

Dahlia Biosciences specializes in the fields of biotechnology and DNA analysis and diagnostics. The company provides a single-cell RNA analysis tools for research and diagnostic applications. Dahlia Biosciences was founded in 2011 and headquartered in California, United States.

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing gene therapy treatments specifically for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, the company utilizes proprietary technology to deliver therapeutic DNA directly to intestinal stem cells, aiming to address the underlying causes of diseases such as Familial Adenomatous Polyposis (FAP), a hereditary form of colorectal cancer that often necessitates invasive surgical procedures. By targeting these root causes, DNALite seeks to prevent disease progression rather than merely managing symptoms, offering a potentially transformative approach to treating gastrointestinal disorders, including colorectal cancer and Crohn's disease.

Osiris Bio

Moirai Biodesign develops RNA-based therapies and diagnostics for cancer. The company develops non-invasive tests for in-vitro and in-situ diagnosis of AML using the patients blood; in-vivo diagnosis systems for surgical assistance and patient monitoring; and therapeutical drugs for treating cancer. Its pipeline includes RNA biomarker discovery, plug and play bio device design, and platform delivery system. The company was founded in 2016 and is based in Ireland.

Chronomics Ltd, established in 2017 and headquartered in Norwich, United Kingdom, specializes in testing kits and an artificial intelligence platform designed for DNA methylation analysis. The company focuses on monitoring users' health and wellbeing by utilizing epigenetic information derived from DNA. Its offerings include insights into biological age, smoke exposure, metabolic state, health risks, and hereditary intolerances, along with predictions related to eye color. Through its innovative approach, Chronomics aims to provide a comprehensive understanding of individual health profiles.

Magellan Life Sciences Ltd. is a synthetic biology company based in London, United Kingdom, established in 2018. The company specializes in developing proprietary protein engineering and expression platforms to create innovative plant-inspired proteins, such as brazzein, for applications in the food and beverage industries. Additionally, Magellan Life Sciences offers the XSeed platform, which leverages synthetic biology to advance the development of novel proteins aimed at enhancing the food, health, and nutrition sectors.

Sun Genomics, Inc. is a microbiome health company based in San Diego, California, specializing in customized probiotics aimed at addressing dysbiosis. Founded in 2014, the company’s flagship product, Floré, combines a gut microbiome test with personalized probiotic formulations tailored to individual gut profiles, assessed through whole-genome sequencing. The Floré Gut Test includes a microflora collection kit, a comprehensive microflora profile analysis, and wellness consultations. Additionally, Sun Genomics offers Floré Tots, a probiotic solution designed for children up to age 12, which comes in a convenient powder form that can be easily mixed with beverages. The company sells its products online, providing an automatic renewal service to enhance customer convenience.

Dahlia Biosciences specializes in the fields of biotechnology and DNA analysis and diagnostics. The company provides a single-cell RNA analysis tools for research and diagnostic applications. Dahlia Biosciences was founded in 2011 and headquartered in California, United States.

Onconetics Pharmaceuticals, Inc. is a biotech company focused on developing innovative gene therapies aimed at targeting tumor cells based on specific gene expression profiles. By utilizing a genetic switch to activate an apoptotic inducer, the therapies aim to eliminate cancer cells while preserving healthy tissue. Founded in 2016 and located in Mill Valley, California, the company is dedicated to advancing personalized medicine, particularly in the treatment of cancer and genetic disorders. Onconetics combines established gene therapy techniques with cutting-edge research to create novel treatments that seek to minimize the invasiveness, cost, and uncertainty associated with traditional cancer therapies. The goal is to develop simpler and more versatile personalized therapies that maintain patient quality of life and enhance understanding of genetic conditions.

Catalog Technologies Inc. is a Boston-based company that specializes in a DNA-based platform designed for digital data storage and computation. Founded in 2016, Catalog's innovative platform encodes digital information into DNA, providing a new approach to long-term data archiving. This method not only enhances data storage capacity but also offers a cost-effective solution for managing vast amounts of information. By integrating advanced synthetic biology technologies, Catalog aims to revolutionize the way digital data is archived and processed, making DNA a viable medium for future data storage needs.

Indee Labs is developing hardware for gene delivery. Our hardware is uniquely positioned for the efficient development and scalable manufacture of gene-modified cell therapies such as chimeric antigen receptor T cells. The technology is being developed with the help of the Australian National Fabrication Facility. We are alumni of NSW Health, IndieBio, Y Combinator and MBC Biolabs (née QB3@953). We are opening up an office in Sydney and have lab space at Bonneville Labs in Berkeley.

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing gene therapy treatments specifically for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, the company utilizes proprietary technology to deliver therapeutic DNA directly to intestinal stem cells, aiming to address the underlying causes of diseases such as Familial Adenomatous Polyposis (FAP), a hereditary form of colorectal cancer that often necessitates invasive surgical procedures. By targeting these root causes, DNALite seeks to prevent disease progression rather than merely managing symptoms, offering a potentially transformative approach to treating gastrointestinal disorders, including colorectal cancer and Crohn's disease.

Jungla Inc., headquartered in South San Francisco, is a biotechnology company focused on enhancing disease diagnosis and drug development through its molecular function software platform. Established in 2016, the company integrates advancements in functional genomics, computational biophysics, and computer science to provide healthcare and drug companies with quantitative, model-driven insights into genomic variants. This innovative approach aims to improve the accuracy of clinical genetic testing, addressing shortcomings in existing market solutions. By delivering robust and scalable results, Jungla empowers healthcare providers to expedite diagnostic development and treatment processes. As a subsidiary of Invitae Corporation, Jungla is supported by prominent technology and healthcare investors, reflecting its commitment to advancing precision medicine.

Ravata Solutions, founded in 2016 and based in Davis, California, specializes in developing medical devices for gene delivery, focusing on the creation of custom animal models. The company is dedicated to enhancing the production of transgenic models, which are crucial for pre-clinical research studies aimed at improving human disease modeling. By optimizing embryo viability and streamlining the process of creating transgenic organisms, Ravata enables researchers to conduct their studies more efficiently. This innovation has significant implications for advancing drug efficacy and medical genetics research, ultimately contributing to the development of better therapies and understanding of human diseases.

Ravata Solutions, founded in 2016 and based in Davis, California, specializes in developing medical devices for gene delivery, focusing on the creation of custom animal models. The company is dedicated to enhancing the production of transgenic models, which are crucial for pre-clinical research studies aimed at improving human disease modeling. By optimizing embryo viability and streamlining the process of creating transgenic organisms, Ravata enables researchers to conduct their studies more efficiently. This innovation has significant implications for advancing drug efficacy and medical genetics research, ultimately contributing to the development of better therapies and understanding of human diseases.

Catalog Technologies Inc. is a Boston-based company that specializes in a DNA-based platform designed for digital data storage and computation. Founded in 2016, Catalog's innovative platform encodes digital information into DNA, providing a new approach to long-term data archiving. This method not only enhances data storage capacity but also offers a cost-effective solution for managing vast amounts of information. By integrating advanced synthetic biology technologies, Catalog aims to revolutionize the way digital data is archived and processed, making DNA a viable medium for future data storage needs.

Ranomics, Inc. is a biotechnology company established in 2015, with headquarters in San Francisco, California, and an additional location in Toronto, Canada. The company specializes in providing a comprehensive database of rare genetic variations and associated disease risks, aimed at enhancing the understanding of how genetic makeup influences health. Ranomics offers tools such as RanomicsDB, a query interface that supports variant call format (VCF) data, and the Ranomics API, which allows developers to integrate genetic data into their existing software for variant interpretation. By delivering insights into genetic variations and health predictions, Ranomics enables healthcare professionals to assess genetic changes efficiently and cost-effectively, thereby contributing to advancements in personalized medicine and drug discovery.

Girihlet Inc. is a genetic-sequencing company based in Oakland, California, established in 2012. It specializes in providing rapid and accurate deep sequencing services, focusing on non-canonical genomics solutions. The company employs novel, bias-free methods to inexpensively sequence and analyze mitochondrial DNA and T cell receptors. By profiling the T cell receptor repertoire, Girihlet aims to improve understanding of the immune system, particularly in relation to T-cell-driven autoimmune conditions. The company leverages deep sequencing and machine learning to decode individual immune responses, thereby guiding therapeutic strategies and enhancing diagnostic capabilities for various disorders. Through its patented technologies, Girihlet seeks to make a significant impact in clinical settings and advance basic research in immunology.

Moirai Biodesign develops RNA-based therapies and diagnostics for cancer. The company develops non-invasive tests for in-vitro and in-situ diagnosis of AML using the patients blood; in-vivo diagnosis systems for surgical assistance and patient monitoring; and therapeutical drugs for treating cancer. Its pipeline includes RNA biomarker discovery, plug and play bio device design, and platform delivery system. The company was founded in 2016 and is based in Ireland.

Jungla Inc., headquartered in South San Francisco, is a biotechnology company focused on enhancing disease diagnosis and drug development through its molecular function software platform. Established in 2016, the company integrates advancements in functional genomics, computational biophysics, and computer science to provide healthcare and drug companies with quantitative, model-driven insights into genomic variants. This innovative approach aims to improve the accuracy of clinical genetic testing, addressing shortcomings in existing market solutions. By delivering robust and scalable results, Jungla empowers healthcare providers to expedite diagnostic development and treatment processes. As a subsidiary of Invitae Corporation, Jungla is supported by prominent technology and healthcare investors, reflecting its commitment to advancing precision medicine.

DNA sequencing is driving the new genomic revolution but it’s currently bottlenecked with high compute costs and inaccuracies. Genome Surveillance is revolutionizing DNA sequencing to make it ten times faster and more accurate through reducing the heavy computational load and dropping it to a fraction of the cost of current technologies.

Amaryllis Nucleics, Inc. is a biotechnology company based in Berkeley, California, specializing in the manufacture of RNA sequencing library synthesis kits. Founded in 2016, the company provides a range of RNA sequencing solutions, including kits for detecting differential gene expression, splice variants, exonic polymorphisms, and gene fusions, as well as 3'-digital gene expression kits for comprehensive gene expression studies. Amaryllis Nucleics also offers RNA sequencing services, catering to applications in cancer diagnostics, pharmaceutical development, and food security. By focusing on reducing the time and cost associated with RNA sequencing, the company aims to empower researchers and facilitate significant advancements in genomics. Its products are available for purchase online.

Genesis DNA is taking a fundamentally new approach to gene synthesis, the process of turning digital text like ACTG into physical DNA. Their proprietary method circumvents the cost, turnaround time, and sequence limiting factors of existing synthesis methods. Genesis was founded by a team of students at Stanford and MIT that have experienced the pain of current DNA construction methods first hand. They started Genesis DNA with the vision that every researcher should have fast, affordable, and secure access to any DNA sequence they need. They believe the next technology revolution will be a biological one.

At DtoR they have developed the PCR of gene expression—a disruptive technology that will revolutionize the tools used to “tune” protein production in any organism. In one step, and for any cell type, they can identify all of the switches regulating expression of the genome, as well as how active they are. They can also rapidly evolve or synthesize new switches to adapt to any application. Applications developed using their platform will lead to improved product yields in bioreactors, engineered specialty crops, optimized cancer therapeutics, and much more. The possibilities are limited only by their partners' imaginations.

Girihlet Inc. is a genetic-sequencing company based in Oakland, California, established in 2012. It specializes in providing rapid and accurate deep sequencing services, focusing on non-canonical genomics solutions. The company employs novel, bias-free methods to inexpensively sequence and analyze mitochondrial DNA and T cell receptors. By profiling the T cell receptor repertoire, Girihlet aims to improve understanding of the immune system, particularly in relation to T-cell-driven autoimmune conditions. The company leverages deep sequencing and machine learning to decode individual immune responses, thereby guiding therapeutic strategies and enhancing diagnostic capabilities for various disorders. Through its patented technologies, Girihlet seeks to make a significant impact in clinical settings and advance basic research in immunology.

Ranomics, Inc. is a biotechnology company established in 2015, with headquarters in San Francisco, California, and an additional location in Toronto, Canada. The company specializes in providing a comprehensive database of rare genetic variations and associated disease risks, aimed at enhancing the understanding of how genetic makeup influences health. Ranomics offers tools such as RanomicsDB, a query interface that supports variant call format (VCF) data, and the Ranomics API, which allows developers to integrate genetic data into their existing software for variant interpretation. By delivering insights into genetic variations and health predictions, Ranomics enables healthcare professionals to assess genetic changes efficiently and cost-effectively, thereby contributing to advancements in personalized medicine and drug discovery.

Briefcase Biotec develops KiloBaser, a Nespresso machine of DNA synthesis - enabling cutting edge research without detours. KiloBaser is a device for printing short synthetic DNA sequences. It enables individual scientists to easily produce the DNA they need on their desktops, while speeding up production of the basics for all genetic engineering and synthetic biology research and development. Headquartered in Graz, Steiermark, KiloBaser was founded in 2013 by Martin Jost and Alexander Murer.

Briefcase Biotec develops KiloBaser, a Nespresso machine of DNA synthesis - enabling cutting edge research without detours. KiloBaser is a device for printing short synthetic DNA sequences. It enables individual scientists to easily produce the DNA they need on their desktops, while speeding up production of the basics for all genetic engineering and synthetic biology research and development. Headquartered in Graz, Steiermark, KiloBaser was founded in 2013 by Martin Jost and Alexander Murer.

Synbiota Inc. is a Toronto-based company founded in 2013 that specializes in synthetic biology through its innovative DNA prototyping platform. This platform enables users to design, build, and grow genetic circuits, facilitating exploration in the field of synthetic biology. Synbiota offers web-based DNA design software, which allows users to conceptualize genetic constructs before assembly, and provides an electronic lab book for logging results throughout the design, assembly, testing, and iteration processes. By virtualizing the research and development pipeline, Synbiota significantly lowers the barriers to creating advanced life science products, enabling a broader range of individuals to leverage biotechnology for applications in medicine, materials, food, and fuel.

Genetic Anomalies developed a digital rights property trading system. It was purchased by THQ for gaming applications of digital content rights in 1999

Net.Genesis Corp. provides software and professional services that help its customers understand, analyze and improve their online businesses. Its software enables companies to collect, store, organize, and analyze detailed information about the online behavior of customers and other visitors on their web sites. Net.Genesis software also enables its customers to import and analyze information about e-customers from other online and off-line software systems and databases. In addition, the company offers professional services including strategic analytic consulting, product implementation, application integration, training programs, and technical support services. The company markets its products and related services in United States, Europe, and Australia. It was founded in 1994 and is headquartered in Cambridge, Massachusetts. As of December 21, 2001, net.Genesis Corp. was acquired by SPSS Inc.